THE GENESIS OF RESOURCE DEVELOPMENT AND **PARTNERSHIPS:** CENETIC TESTING **EDUCATION FOR** FAMILIES

2025 National EHDI Conference Pittsburgh, PA

Janet DesGeorges

Executive Director, Hands & Voices Headquarters





Always start with joy...

Janet DesGeorges

Parent of a D/HH Adult (still on the journey)

Co-founder and Executive Director

Hands & Voices <u>www.handsandvoices.org</u>

Principal Investigator

Family Leadership in Language and Learning

Co-founder and Committee Member

Global Parents of DHH Children

(GPODHH)

http://www.gpodhh.org/





- Understand the Ethical and Emotional Considerations of Genetic Testing in Deaf and Hard of Hearing Children.
- Analyze the Impact of Early Genetic Identification on Family Decision-Making and Support Systems.
- Apply Best Practices for Parent Advocacy Organizations in Navigating Relationships with Pharmaceutical Companies.
 - You can apply this to other relationships!



HANDS & VOICES ORGANIZATIONAL LENS

Framing our conversation today:

- Family-Centered
- Parent Choice Informed decision making and consent
- Individualized ("What works for your child is what makes the choice right.")
- Current Resources/Projects





- Parents
- DHH Leaders
- Professionals
- Students
- State Agencies
- Medical Agencies/Companies
- Other




Cochlear Implants FM System IEP Manual Communication Hearing Aids Sign Language Mainstreaming IFSP Learning Disabilities Residential School American Sign Language Parental Involvement Auditory Verbal Manually Coded English Sign Systems Interpreters peech Therapy Least Restrictive Environment Genetics Amplification Educationa Placement Communication Options Multiple Disabilities Cued Speech Social/Emotional Development Auditory Neuropathy Family Dynamics Cochlear Implants Amplification FSP Parental Involvment Learning Disabilities Cochlear Implants FM System IEP Manual Communication Hearing Aids Sign Language Mainstreaming IFSP Learning Disabilities esidential School American Sign Language Parental Involvement Auditory Verbal Manually Coded English Sign Systems Interpreters Speech Therapy Least Restrictive Environment Genetic Disorders Amplification Educational Placement Communication Options Multiple Disabilities Cued Speech Social/Emotional Development Auditory Neuropathy Family Dynamics Cochlear Implants Amplification IFSP Parental Involvment Learning Disabilities Cochlear Implants FM System IEP Manual Communication Hearing Aids Sign Language nstreaming IFSP Learning Disabilities Residential School American Sign Language Paren Involvement Auditory Verbal Manually Coded English Sign Systems Interpreters Speech erapy Least Restrictive Environment Genetic Disorders Amplification Educational Placeme Communication Options Multiple Disabilities Cued Speech Social/Emotional Development Auditory Neuropath Family Dynamics Cochlear Implants Amplification IFSP Parental





CONSIDERATIONS FOR PARENTS THAT GUIDE OUR GENETIC TESTING RESOURCE DEVELOPMENT:





WHY IS THIS IMPORTANT FOR FAMILIES?

Not just a 'next step' in the process

 The decision to obtain genetic testing is dependent on informed family choice in conjunction with standard confidentiality guidelines (Chu et al., 2015).

Genetic testing. Although an individual family may choose not to participate in genetic testing for a variety of reasons, the American College of Medical Genetics recommends offering genetic counseling and genetic testing for all infants who are deaf or hard of hearing and their families (Alford et al., 2014).



APPLYING BEST PRACTICES IN OUR RELATIONSHIPS

OUR PROJECT PARTNERSHIPS

Akouos/Lilly

- Developing resources for families about genetic testing considerations.
- Serves as sponsor for our H&V Conference.

Sensorion

 Developing resources for professionals about how to talk to families about genetic testing considerations.

Regeneron

Serves as sponsor for our H&V Conference.

Insights from our community

GUIDING PRINCIPLES

Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organization in the field of rare diseases. (Stein, et al. Orphanet Journal of Rare Diseases (2018) 13:18 DOI 10.1186/s13023-018-0761-02) These Guidelines recommend best practices and standards for interactions between patient advocacy organizations and industry.



FOUR AREAS OF ENGAGEMENT BETWEEN PATIENT ADVOCACY ORG. AND BIOPHARMACEUTICAL COMPANIES

- k Identification and Engagement between Companies and patient/parent advocacy organizations
- & Patient Engagement and Patient Privacy
- **&** Financial Contributions
- & Clinical Trial Communication and Support



IDENTIFICATION AND ENGAGEMENT BETWEEN COMPANIES AND ADVOCACY ORGS (TRANSPARENCY)

& Mutually beneficial dialogue and information exchange.

- & Community-wide insight and perspective as needed and appropriate to inform the development efforts and strategic decisions of the company.
- & Strives to collaborate with multiple biopharmaceutical companies to ensure the sustainability of its initiatives and to allow for a diversity of views and therapeutic approaches.



PATIENT ENGAGEMENT AND PATIENT PRIVACY

Engagement:

- Diverse approaches to engaging with companies

 from actively facilitating dialogues to passively
 providing training and education for patient
 community members on best practices.
- Encourages biopharmaceutical companies to obtain insights from group discussion rather than from one-on-one conversation with single individuals.



PATIENT ENGAGEMENT AND PATIENT PRIVACY

Privacy:

- & Assists individual patients in thinking through their decisions about providing information or consent.
- & Helps patients convey their expectations about privacy.
- Ensures that biopharmaceutical companies, and other organizations, have in place at least basic guidelines or a policy for ensuring patient privacy prior to any data collection, including surveys, photographs, video and audio recordings, slide decks, and consent forms.



FINANCIAL CONTRIBUTIONS

A robust advocacy organization is a vital partner to biopharmaceutical companies in the development of potential therapies. Financial resources are a key need for the growth and maintenance of the patient advocacy organization.

X The patient advocacy organization accepts financial contributions that support its stated mission and allow the organization **to maintain its autonomy**. The patient advocacy organization assesses the alignment of mission between the two organizations as part of the funding discussions.



CLINICAL TRIAL COMMUNICATION AND SUPPORT

- The patient advocacy organization acts as a conduit for information about clinical trials by providing education and resources to the patient community
- The choice to participate in any particular trial is an individual one; the patient advocacy organization does not seek to influence that choice, but rather, assists patients and families in making informed decisions through education and awareness.



IN CONCLUSION

- A Parent organizations play a crucial role in empowering families with children who are deaf/hard of hearing/dhh+ by providing vital information, resources, and emotional support.
- We bridge the gap between families, educators, for profit companies, and professionals, ensuring that every child has access to the tools they need to thrive.
- & By fostering a sense of community and advocating for inclusive opportunities, we help parents become confident advocates for their children.
- X Together, we can create a more informed, connected, and supportive environment for children who are deaf and their families.





COMMUNICATION GROUND RULES

- k Identify your role before sharing (parent of DHH child, DHH Leader, professional, etc)
- δ One person at a time
- & Use "I" statements
- 📐 Keep it to about 60 seconds







What makes the choice right?

"Our decision was both right and wrong and demonstrates how perplexing and delicate choices like these are to make & accept."

> -David Seerman (Changed By a Child, p.96)

> > (c) Hands & Voices 2020

 Share more with us at janet@handsandvoices.org

